Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial - PDF (Russian)

Copyright (c) 2021 Puig L., Bakulev A.L., Kokhan M.M., Samtsov A.V., Khairutdinov V.R., Morozova M.A., Zolkin N.A., Kuryshev I.V., Petrov A.N., Artemeva A.V., Zinkina-Orikhan A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies